Advertisement

Journal of Molecular Medicine

, Volume 86, Issue 10, pp 1113–1126 | Cite as

Nuclear factor-kappa B signaling in skeletal muscle atrophy

  • Hong Li
  • Shweta Malhotra
  • Ashok KumarEmail author
Review

Abstract

Skeletal muscle atrophy/wasting is a serious complication of a wide range of diseases and conditions such as aging, disuse, AIDS, chronic obstructive pulmonary disease, space travel, muscular dystrophy, chronic heart failure, sepsis, and cancer. Emerging evidence suggests that nuclear factor-kappa B (NF-κB) is one of the most important signaling pathways linked to the loss of skeletal muscle mass in various physiological and pathophysiological conditions. Activation of NF-κB in skeletal muscle leads to degradation of specific muscle proteins, induces inflammation and fibrosis, and blocks the regeneration of myofibers after injury/atrophy. Recent studies employing genetic mouse models have provided strong evidence that NF-κB can serve as an important molecular target for the prevention of skeletal muscle loss. In this article, we have outlined the current understanding regarding the role of NF-κB in skeletal muscle with particular reference to different models of muscle wasting and the development of novel therapy.

Keywords

Skeletal muscle atrophy NF-κB Muscular dystrophy Cancer COPD 

Abbreviations

AP-1

activator protein-1

CHF

chronic heart failure

COPD

chronic obstructive pulmonary disorder

DMD

Duchenne muscular dystrophy

IFN

interferon

IGF

insulin growth factor

IkB

I kappa B

IKK

IkB kinase

IL

interleukin

LGMD2A

limb-girdle muscular dystrophy type 2A

LLC

Lewis lung carcinoma

MMP

matrix metalloproteinase

MuRF1

muscle RING finger protein 1

NF-κB

nuclear factor-kappa B

NIK

NF-κB-inducing kinase

iNOS

inducible nitric oxide synthase

PDTC

pyrrolidine dithiocarbamate

PIF

proteolysis-inducing factor

TNF

tumor necrosis factor

TWEAK

TNF-related weak inducer of apoptosis

Notes

Acknowledgments

We would like to apologize to the many researchers whose contributions were not cited due to our oversight or space limitation. This work was supported by RO1 grant AG029623 from National Institute of Health (to AK).

References

  1. 1.
    Jackman RW, Kandarian SC (2004) The molecular basis of skeletal muscle atrophy. Am J Physiol Cell Physiol 287:C834–C843PubMedCrossRefGoogle Scholar
  2. 2.
    Kandarian SC, Jackman RW (2006) Intracellular signaling during skeletal muscle atrophy. Muscle Nerve 33:155–165PubMedCrossRefGoogle Scholar
  3. 3.
    Boonyarom O, Inui K (2006) Atrophy and hypertrophy of skeletal muscles: structural and functional aspects. Acta Physiol (Oxf) 188:77–89Google Scholar
  4. 4.
    Tisdale MJ (2004) Cancer cachexia. Langenbecks Arch Surg 389:299–305PubMedCrossRefGoogle Scholar
  5. 5.
    Ventadour S, Attaix D (2006) Mechanisms of skeletal muscle atrophy. Curr Opin Rheumatol 18:631–635PubMedCrossRefGoogle Scholar
  6. 6.
    Eley HL, Tisdale MJ (2007) Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation. J Biol Chem 282:7087–7097PubMedCrossRefGoogle Scholar
  7. 7.
    Kandarian SC, Stevenson EJ (2002) Molecular events in skeletal muscle during disuse atrophy. Exerc Sport Sci Rev 30:111–116PubMedCrossRefGoogle Scholar
  8. 8.
    McKinnell IW, Rudnicki MA (2004) Molecular mechanisms of muscle atrophy. Cell 119:907–910PubMedCrossRefGoogle Scholar
  9. 9.
    Guttridge DC (2004) Signaling pathways weigh in on decisions to make or break skeletal muscle. Curr Opin Clin Nutr Metab Care 7:443–450PubMedCrossRefGoogle Scholar
  10. 10.
    Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, Shoelson SE (2004) IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119:285–298PubMedCrossRefGoogle Scholar
  11. 11.
    Hunter RB, Kandarian SC (2004) Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy. J Clin Invest 114:1504–1511PubMedGoogle Scholar
  12. 12.
    Mourkioti F, Kratsios P, Luedde T, Song YH, Delafontaine P, Adami R, Parente V, Bottinelli R, Pasparakis M, Rosenthal N (2006) Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J Clin Invest 116:2945–2954PubMedCrossRefGoogle Scholar
  13. 13.
    Acharyya S, Villalta SA, Bakkar N, Bupha-Intr T, Janssen PM, Carathers M, Li ZW, Beg AA, Ghosh S, Sahenk Z, Weinstein M, Gardner KL, Rafael-Fortney JA, Karin M, Tidball JG, Baldwin AS, Guttridge DC (2007) Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 117:889–901PubMedCrossRefGoogle Scholar
  14. 14.
    Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18:2195–2224PubMedCrossRefGoogle Scholar
  15. 15.
    Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132:344–362PubMedCrossRefGoogle Scholar
  16. 16.
    Kumar A, Takada Y, Boriek AM, Aggarwal BB (2004) Nuclear factor-kappaB: its role in health and disease. J Mol Med 82:434–448PubMedCrossRefGoogle Scholar
  17. 17.
    Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3:745–756PubMedCrossRefGoogle Scholar
  18. 18.
    Li Q, Verma IM (2002) NF-kappaB regulation in the immune system. Nat Rev Immunol 2:725–734PubMedCrossRefGoogle Scholar
  19. 19.
    Hunter RB, Stevenson E, Koncarevic A, Mitchell-Felton H, Essig DA, Kandarian SC (2002) Activation of an alternative NF-kappaB pathway in skeletal muscle during disuse atrophy. FASEB J 16:529–538PubMedCrossRefGoogle Scholar
  20. 20.
    Cao PR, Kim HJ, Lecker SH (2005) Ubiquitin-protein ligases in muscle wasting. Int J Biochem Cell Biol 37:2088–2097PubMedCrossRefGoogle Scholar
  21. 21.
    Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL (2001) Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 98:14440–14445PubMedCrossRefGoogle Scholar
  22. 22.
    Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294:1704–1708PubMedCrossRefGoogle Scholar
  23. 23.
    Whitehouse AS, Tisdale MJ (2003) Increased expression of the ubiquitin–proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-kappaB. Br J Cancer 89:1116–1122PubMedCrossRefGoogle Scholar
  24. 24.
    Spate U, Schulze PC (2004) Proinflammatory cytokines and skeletal muscle. Curr Opin Clin Nutr Metab Care 7:265–269PubMedCrossRefGoogle Scholar
  25. 25.
    Debigare R, Cote CH, Maltais F (2001) Peripheral muscle wasting in chronic obstructive pulmonary disease. Clinical relevance and mechanisms. Am J Respir Crit Care Med 164:1712–1717PubMedGoogle Scholar
  26. 26.
    Roubenoff R (2003) Catabolism of aging: is it an inflammatory process? Curr Opin Clin Nutr Metab Care 6:295–299PubMedCrossRefGoogle Scholar
  27. 27.
    Phillips T, Leeuwenburgh C (2005) Muscle fiber specific apoptosis and TNF-alpha signaling in sarcopenia are attenuated by life-long calorie restriction. FASEB J 19:668–670PubMedGoogle Scholar
  28. 28.
    Fernandez-Celemin L, Pasko N, Blomart V, Thissen JP (2002) Inhibition of muscle insulin-like growth factor I expression by tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab 283:E1279–E1290PubMedGoogle Scholar
  29. 29.
    Foulstone EJ, Meadows KA, Holly JM, Stewart CE (2001) Insulin-like growth factors (IGF-I and IGF-II) inhibit C2 skeletal myoblast differentiation and enhance TNF alpha-induced apoptosis. J Cell Physiol 189:207–215PubMedCrossRefGoogle Scholar
  30. 30.
    Demoule A, Divangahi M, Danialou G, Gvozdic D, Larkin G, Bao W, Petrof BJ (2005) Expression and regulation of CC class chemokines in the dystrophic (mdx) diaphragm. Am J Respir Cell Mol Biol 33:178–185PubMedCrossRefGoogle Scholar
  31. 31.
    Srivastava AK, Qin X, Wedhas N, Arnush M, Linkhart TA, Chadwick RB, Kumar A (2007) Tumor necrosis factor-alpha augments matrix metalloproteinase-9 production in skeletal muscle cells through the activation of transforming growth factor-beta-activated kinase 1 (TAK1)-dependent signaling pathway. J Biol Chem 282:35113–35124PubMedCrossRefGoogle Scholar
  32. 32.
    Charge SB, Rudnicki MA (2004) Cellular and molecular regulation of muscle regeneration. Physiol Rev 84:209–238PubMedCrossRefGoogle Scholar
  33. 33.
    Langen RC, Schols AM, Kelders MC, van der Velden JL, Wouters EF, Janssen-Heininger YM (2006) Muscle wasting and impaired muscle regeneration in a murine model of chronic pulmonary inflammation. Am J Respir Cell Mol Biol 35:689–696PubMedCrossRefGoogle Scholar
  34. 34.
    Langen RC, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM (2001) Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. FASEB J 15:1169–1180PubMedCrossRefGoogle Scholar
  35. 35.
    Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr (1999) NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19:5785–5799PubMedGoogle Scholar
  36. 36.
    Mitin N, Kudla AJ, Konieczny SF, Taparowsky EJ (2001) Differential effects of Ras signaling through NFkappaB on skeletal myogenesis. Oncogene 20:1276–1286PubMedCrossRefGoogle Scholar
  37. 37.
    Lehtinen SK, Rahkila P, Helenius M, Korhonen P, Salminen A (1996) Down-regulation of transcription factors AP-1, Sp-1, and NF-kappa B precedes myocyte differentiation. Biochem Biophys Res Commun 229:36–43PubMedCrossRefGoogle Scholar
  38. 38.
    Wang H, Hertlein E, Bakkar N, Sun H, Acharyya S, Wang J, Carathers M, Davuluri R, Guttridge DC (2007) NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol Cell Biol 27:4374–4387PubMedCrossRefGoogle Scholar
  39. 39.
    Thaloor D, Miller KJ, Gephart J, Mitchell PO, Pavlath GK (1999) Systemic administration of the NF-kappaB inhibitor curcumin stimulates muscle regeneration after traumatic injury. Am J Physiol 277:C320–C329PubMedGoogle Scholar
  40. 40.
    Shishodia S, Sethi G, Aggarwal BB (2005) Curcumin: getting back to the roots. Ann N Y Acad Sci 1056:206–217PubMedCrossRefGoogle Scholar
  41. 41.
    Dogra C, Changotra H, Wedhas N, Qin X, Wergedal JE, Kumar A (2007) TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J 21:1857–1869PubMedCrossRefGoogle Scholar
  42. 42.
    Dogra C, Changotra H, Mohan S, Kumar A (2006) Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-kappaB and degradation of MyoD protein. J Biol Chem 281:10327–10336PubMedCrossRefGoogle Scholar
  43. 43.
    Berkes CA, Tapscott SJ (2005) MyoD and the transcriptional control of myogenesis. Semin Cell Dev Biol 16:585–595PubMedCrossRefGoogle Scholar
  44. 44.
    Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS Jr (2000) NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 289:2363–2366PubMedCrossRefGoogle Scholar
  45. 45.
    Sitcheran R, Cogswell PC, Baldwin AS Jr (2003) NF-kappaB mediates inhibition of mesenchymal cell differentiation through a posttranscriptional gene silencing mechanism. Genes Dev 17:2368–2373PubMedCrossRefGoogle Scholar
  46. 46.
    Di Marco S, Mazroui R, Dallaire P, Chittur S, Tenenbaum SA, Radzioch D, Marette A, Gallouzi IE (2005) NF-kappa B-mediated MyoD decay during muscle wasting requires nitric oxide synthase mRNA stabilization, HuR protein, and nitric oxide release. Mol Cell Biol 25:6533–6545PubMedCrossRefGoogle Scholar
  47. 47.
    Kaliman P, Canicio J, Testar X, Palacin M, Zorzano A (1999) Insulin-like growth factor-II, phosphatidylinositol 3-kinase, nuclear factor-kappaB and inducible nitric-oxide synthase define a common myogenic signaling pathway. J Biol Chem 274:17437–17444PubMedCrossRefGoogle Scholar
  48. 48.
    Canicio J, Ruiz-Lozano P, Carrasco M, Palacin M, Chien K, Zorzano A, Kaliman P (2001) Nuclear factor kappa B-inducing kinase and Ikappa B kinase-alpha signal skeletal muscle cell differentiation. J Biol Chem 276:20228–20233PubMedCrossRefGoogle Scholar
  49. 49.
    Bakkar N, Wang J, Ladner KJ, Wang H, Dahlman JM, Carathers M, Acharyya S, Rudnicki MA, Hollenbach AD, Guttridge DC (2008) IKK/NF-kappaB regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis. J Cell Biol 180:787–802PubMedCrossRefGoogle Scholar
  50. 50.
    Dalkilic I, Kunkel LM (2003) Muscular dystrophies: genes to pathogenesis. Curr Opin Genet Dev 13:231–238PubMedCrossRefGoogle Scholar
  51. 51.
    Hoffman EP, Brown RH, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51:919–928PubMedCrossRefGoogle Scholar
  52. 52.
    Spencer MJ, Montecino-Rodriguez E, Dorshkind K, Tidball JG (2001) Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle. Clin Immunol 98:235–243PubMedCrossRefGoogle Scholar
  53. 53.
    Chen YW, Zhao P, Borup R, Hoffman EP (2000) Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol 151:1321–1336PubMedCrossRefGoogle Scholar
  54. 54.
    Tidball JG, Wehling-Henricks M (2004) Evolving therapeutic strategies for Duchenne muscular dystrophy: targeting downstream events. Pediatr Res 56:831–841PubMedCrossRefGoogle Scholar
  55. 55.
    Kumar A, Boriek AM (2003) Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. FASEB J 17:386–396PubMedCrossRefGoogle Scholar
  56. 56.
    Monici MC, Aguennouz M, Mazzeo A, Messina C, Vita G (2003) Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology 60:993–997PubMedGoogle Scholar
  57. 57.
    Carlson CG, Samadi A, Siegel A (2005) Chronic treatment with agents that stabilize cytosolic IkappaB-alpha enhances survival and improves resting membrane potential in MDX muscle fibers subjected to chronic passive stretch. Neurobiol Dis 20:719–730PubMedCrossRefGoogle Scholar
  58. 58.
    Messina S, Bitto A, Aguennouz M, Minutoli L, Monici MC, Altavilla D, Squadrito F, Vita G (2006) Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice. Exp Neurol 198:234–241PubMedCrossRefGoogle Scholar
  59. 59.
    Messina S, Altavilla D, Aguennouz M, Seminara P, Minutoli L, Monici MC, Bitto A, Mazzeo A, Marini H, Squadrito F, Vita G (2006) Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice. Am J Pathol 168:918–926PubMedCrossRefGoogle Scholar
  60. 60.
    Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270:286–290PubMedCrossRefGoogle Scholar
  61. 61.
    Richard I, Roudaut C, Marchand S, Baghdiguian S, Herasse M, Stockholm D, Ono Y, Suel L, Bourg N, Sorimachi H, Lefranc G, Fardeau M, Sebille A, Beckmann JS (2000) Loss of calpain 3 proteolytic activity leads to muscular dystrophy and to apoptosis-associated IkappaBalpha/nuclear factor kappaB pathway perturbation in mice. J Cell Biol 151:1583–1590PubMedCrossRefGoogle Scholar
  62. 62.
    Baghdiguian S, Martin M, Richard I, Pons F, Astier C, Bourg N, Hay RT, Chemaly R, Halaby G, Loiselet J, Anderson LV, Lopez de Munain A, Fardeau M, Mangeat P, Beckmann JS, Lefranc G (1999) Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkappaB alpha/NF-kappaB pathway in limb-girdle muscular dystrophy type 2A. Nat Med 5:503–511PubMedCrossRefGoogle Scholar
  63. 63.
    Benayoun B, Baghdiguian S, Lajmanovich A, Bartoli M, Daniele N, Gicquel E, Bourg N, Raynaud F, Pasquier MA, Suel L, Lochmuller H, Lefranc G, Richard I (2007) NF-{kappa}B-dependent expression of the antiapoptotic factor c-FLIP is regulated by calpain 3, the protein involved in limb-girdle muscular dystrophy type 2A. FASEB J 22:1521–1529PubMedCrossRefGoogle Scholar
  64. 64.
    Deans C, Wigmore SJ (2005) Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 8:265–269PubMedCrossRefGoogle Scholar
  65. 65.
    Wyke SM, Russell ST, Tisdale MJ (2004) Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation. Br J Cancer 91:1742–1750PubMedGoogle Scholar
  66. 66.
    Moore-Carrasco R, Busquets S, Almendro V, Palanki M, Lopez-Soriano FJ, Argiles JM (2007) The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. Int J Oncol 30:1239–1245PubMedGoogle Scholar
  67. 67.
    Wang Z, Corey E, Hass GM, Higano CS, True LD, Wallace D Jr, Tisdale MJ, Vessella RL (2003) Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia. Int J Cancer 105:123–129PubMedCrossRefGoogle Scholar
  68. 68.
    Jiang Z, Clemens PR (2006) Cellular caspase-8-like inhibitory protein (cFLIP) prevents inhibition of muscle cell differentiation induced by cancer cells. FASEB J 20:2570–2572PubMedCrossRefGoogle Scholar
  69. 69.
    Kuroda K, Horiguchi Y, Nakashima J, Kikuchi E, Kanao K, Miyajima A, Ohigashi T, Umezawa K, Murai M (2005) Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer. Clin Cancer Res 11:5590–5594PubMedCrossRefGoogle Scholar
  70. 70.
    Juttler E, Potrovita I, Tarabin V, Prinz S, Dong-Si T, Fink G, Schwaninger M (2004) The cannabinoid dexanabinol is an inhibitor of the nuclear factor-kappa B (NF-kappa B). Neuropharmacology 47:580–592PubMedCrossRefGoogle Scholar
  71. 71.
    Mishra A, Chaudhary A, Sethi S (2004) Oxidized omega-3 fatty acids inhibit NF-kappaB activation via a PPARalpha-dependent pathway. Arterioscler Thromb Vasc Biol 24:1621–1627PubMedCrossRefGoogle Scholar
  72. 72.
    Li WG, Gavrila D, Liu X, Wang L, Gunnlaugsson S, Stoll LL, McCormick ML, Sigmund CD, Tang C, Weintraub NL (2004) Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation 109:2221–2226PubMedCrossRefGoogle Scholar
  73. 73.
    Futakuchi M, Ogawa K, Tamano S, Takahashi S, Shirai T (2004) Suppression of metastasis by nuclear factor kappaB inhibitors in an in vivo lung metastasis model of chemically induced hepatocellular carcinoma. Cancer Sci 95:18–24PubMedCrossRefGoogle Scholar
  74. 74.
    Majumdar S, Lamothe B, Aggarwal BB (2002) Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol 168:2644–2651PubMedGoogle Scholar
  75. 75.
    Gilad E, Wong HR, Zingarelli B, Virag L, O’Connor M, Salzman AL, Szabo C (1998) Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFkappaB activation. FASEB J 12:685–693PubMedGoogle Scholar
  76. 76.
    Penner CG, Gang G, Wray C, Fischer JE, Hasselgren PO (2001) The transcription factors NF-kappab and AP-1 are differentially regulated in skeletal muscle during sepsis. Biochem Biophys Res Commun 281:1331–1336PubMedCrossRefGoogle Scholar
  77. 77.
    Frost RA, Lang CH (2005) Skeletal muscle cytokines: regulation by pathogen-associated molecules and catabolic hormones. Curr Opin Clin Nutr Metab Care 8:255–263PubMedGoogle Scholar
  78. 78.
    Callahan LA, Nethery D, Stofan D, DiMarco A, Supinski G (2001) Free radical-induced contractile protein dysfunction in endotoxin-induced sepsis. Am J Respir Cell Mol Biol 24:210–217PubMedGoogle Scholar
  79. 79.
    Boyd JH, Divangahi M, Yahiaoui L, Gvozdic D, Qureshi S, Petrof BJ (2006) Toll-like receptors differentially regulate CC and CXC chemokines in skeletal muscle via NF-kappaB and calcineurin. Infect Immun 74:6829–6838PubMedCrossRefGoogle Scholar
  80. 80.
    Demoule A, Divangahi M, Yahiaoui L, Danialou G, Gvozdic D, Labbe K, Bao W, Petrof BJ (2006) Endotoxin triggers nuclear factor-kappaB-dependent up-regulation of multiple proinflammatory genes in the diaphragm. Am J Respir Crit Care Med 174:646–653PubMedCrossRefGoogle Scholar
  81. 81.
    Casadevall C, Coronell C, Ramirez-Sarmiento AL, Martinez-Llorens J, Barreiro E, Orozco-Levi M, Gea J (2007) Upregulation of pro-inflammatory cytokines in the intercostal muscles of COPD patients. Eur Respir J 30:701–707PubMedCrossRefGoogle Scholar
  82. 82.
    Gosker HR, Wouters EF, van der Vusse GJ, Schols AM (2000) Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: underlying mechanisms and therapy perspectives. Am J Clin Nutr 71:1033–1047PubMedGoogle Scholar
  83. 83.
    Staib JL, Swoap SJ, Powers SK (2002) Diaphragm contractile dysfunction in MyoD gene-inactivated mice. Am J Physiol Regul Integr Comp Physiol 283:R583–R590PubMedGoogle Scholar
  84. 84.
    Agusti A, Morla M, Sauleda J, Saus C, Busquets X (2004) NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax 59:483–487PubMedCrossRefGoogle Scholar
  85. 85.
    Broekhuizen R, Wouters EF, Creutzberg EC, Weling-Scheepers CA, Schols AM (2005) Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary disease. Thorax 60:376–382PubMedCrossRefGoogle Scholar
  86. 86.
    Bolger AP, Anker SD (2000) Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications. Drugs 60:1245–1257PubMedCrossRefGoogle Scholar
  87. 87.
    Adams V, Nehrhoff B, Spate U, Linke A, Schulze PC, Baur A, Gielen S, Hambrecht R, Schuler G (2002) Induction of iNOS expression in skeletal muscle by IL-1beta and NFkappaB activation: an in vitro and in vivo study. Cardiovasc Res 54:95–104PubMedCrossRefGoogle Scholar
  88. 88.
    Adams V, Spate U, Krankel N, Schulze PC, Linke A, Schuler G, Hambrecht R (2003) Nuclear factor-kappa B activation in skeletal muscle of patients with chronic heart failure: correlation with the expression of inducible nitric oxide synthase. Eur J Cardiovasc Prev Rehabil 10:273–277PubMedCrossRefGoogle Scholar
  89. 89.
    Jankowska EA, von Haehling S, Czarny A, Zaczynska E, Kus A, Anker SD, Banasiak W, Ponikowski P (2005) Activation of the NF-kappaB system in peripheral blood leukocytes from patients with chronic heart failure. Eur J Heart Fail 7:984–990PubMedCrossRefGoogle Scholar
  90. 90.
    Siednienko J, Jankowska EA, Banasiak W, Gorczyca WA, Ponikowski P (2007) Nuclear factor-kappaB activity in peripheral blood mononuclear cells in cachectic and non-cachectic patients with chronic heart failure. Int J Cardiol 122:111–116PubMedCrossRefGoogle Scholar
  91. 91.
    Mitch WE, Bailey JL, Wang X, Jurkovitz C, Newby D, Price SR (1999) Evaluation of signals activating ubiquitin–proteasome proteolysis in a model of muscle wasting. Am J Physiol 276:C1132–C1138PubMedGoogle Scholar
  92. 92.
    Guillet C, Boirie Y (2005) Insulin resistance: a contributing factor to age-related muscle mass loss? Diabetes Metab 31(Spec No 2):5S20–25S26PubMedCrossRefGoogle Scholar
  93. 93.
    Willey KA, Singh MA (2003) Battling insulin resistance in elderly obese people with type 2 diabetes: bring on the heavy weights. Diabetes Care 26:1580–1588PubMedCrossRefGoogle Scholar
  94. 94.
    Li YP, Chen Y, Li AS, Reid MB (2003) Hydrogen peroxide stimulates ubiquitin-conjugating activity and expression of genes for specific E2 and E3 proteins in skeletal muscle myotubes. Am J Physiol Cell Physiol 285:C806–C812PubMedGoogle Scholar
  95. 95.
    Mastrocola R, Reffo P, Penna F, Tomasinelli CE, Boccuzzi G, Baccino FM, Aragno M, Costelli P (2008) Muscle wasting in diabetic and in tumor-bearing rats: role of oxidative stress. Free Radic Biol Med 44:584–593PubMedCrossRefGoogle Scholar
  96. 96.
    Judge AR, Koncarevic A, Hunter RB, Liou HC, Jackman RW, Kandarian SC (2007) Role for IkappaBalpha, but not c-Rel, in skeletal muscle atrophy. Am J Physiol Cell Physiol 292:C372–C382PubMedCrossRefGoogle Scholar
  97. 97.
    Degens H, Alway SE (2006) Control of muscle size during disuse, disease, and aging. Int J Sports Med 27:94–99PubMedCrossRefGoogle Scholar
  98. 98.
    Bruunsgaard H, Pedersen BK (2003) Age-related inflammatory cytokines and disease. Immunol Allergy Clin North Am 23:15–39PubMedCrossRefGoogle Scholar
  99. 99.
    Bar-Shai M, Carmeli E, Coleman R, Rozen N, Perek S, Fuchs D, Reznick AZ (2005) The effect of hindlimb immobilization on acid phosphatase, metalloproteinases and nuclear factor-kappaB in muscles of young and old rats. Mech Ageing Dev 126:289–297PubMedCrossRefGoogle Scholar
  100. 100.
    Cuthbertson D, Smith K, Babraj J, Leese G, Waddell T, Atherton P, Wackerhage H, Taylor PM, Rennie MJ (2005) Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. FASEB J 19:422–424PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Department of Anatomical Sciences and NeurobiologyUniversity of Louisville School of MedicineLouisvilleUSA

Personalised recommendations